Qin B, Xin L, Hou Q, et al. - Researchers retrospectively inquired about the efficacy as well as the safety of anlotinib as second or later line therapy in small-cell lung cancer (SCLC) patients in their center, as well as investigated risk factors for predicting the clinical advantage of anlotinib. Participants were 29 SCLC patients managed with anlotinib monotherapy or combination therapy as second or later line therapy. In the whole study sample, a median progression-free survival (PFS) of 2.1 months, and objective response rate and disease control rate of 10.3% and 48.3%, respectively, were obtained; the median overall survival was 7.2 months. In Cox regression analysis, the identified independent risk factor for PFS was response to first-line treatment. Findings demonstrated the effectiveness of anlotinib as a therapeutic choice for SCLC with tolerable toxicity as second or later line treatment. Longer PFS in relation to treatment with anlotinib was noted in patients sensitive to first-line treatment. The combination of anloitnib with other therapy resulted in an increase in the efficacy without adding toxicity.